Protein / target
Tissue factor
Protein at a glance
Biological role
Cytokine receptor activity
Primary system
Immune system
Strongest disease association
placental abruption
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
1 approved
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited proteolysis. TF plays a role in normal hemostasis by initiating the cell-surface assembly and propagation of the coagulation protease cascade
Subcellular location
Domains and Gene Ontology detail (24)Hide
Gene Ontology
- Ccell surface
- Cexternal side of plasma membrane
- Cextracellular matrix
- Cextracellular space
- Cmembrane
- Cplasma membrane
- Cserine-type peptidase complex
- Fcytokine receptor activity
- Fphospholipid binding
- Fprotease binding
- Pactivation of blood coagulation via clotting cascade
- Pactivation of plasma proteins involved in acute inflammatory response
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Haemostasis
- ·Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. Th…
- ·activation of blood coagulation via clotting cascade
- ·blood coagulation
- ·positive regulation of platelet-derived growth factor receptor signaling pathway
Proteolysis
- ·Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. Th…
- ·protease binding
Transcriptional regulation
- ·positive regulation of gene expression
- ·NGF-stimulated transcription
Immune signalling
- ·cytokine receptor activity
- ·activation of plasma proteins involved in acute inflammatory response
- ·cytokine-mediated signaling pathway
- ·positive regulation of interleukin-8 production
Cell adhesion
- ·extracellular matrix
Apoptosis & cell death
- ·positive regulation of endothelial cell apoptotic process
View underlying pathways (3)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Coagulation factor III binding agent
Appears in clinical studies involving cervical cancer, cervical cancer, cancer, neoplasm
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 1,435 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 1 total
cervical cancer · cervical cancer · cancer
Tractability
Safety liabilities
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (6)Hide
ClinicalTrials.gov via the drug-target graph.
Related literature
Papers indexed under “Thromboplastin” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: Tivdak (EMA)
- New publicationTisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
- New publicationTisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.